Stock Market Reviews

TNGX (Tango Therapeutics, Inc.) News

Get the latest news, insights, and market updates on TNGX (Tango Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• 3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026
  EyePoint, ANI Pharmaceuticals and Tango Therapeutics put up a stellar show in 2025 and are set to carry the momentum in 2026 as well.
  Dec 22, 2025 - $TNGX
• 5 Biotech Stocks to Watch for Potential Upside
  New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.
  Dec 17, 2025 - $TNGX
• Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference
  BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:45am PST/12:45pm EST. The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A repl
  Dec 17, 2025 - $TNGX
• Is Tango Therapeutics (TNGX) Overvalued After a 200% One-Year Surge? A Fresh Look at Its Pricing
  Tango Therapeutics (TNGX) has quietly turned into a strong performer, with the stock up roughly 200% this year and more than tripling over the past year as investors reassess its oncology pipeline. See our latest analysis for Tango Therapeutics. The latest moves have been choppy, with a 14.44% 1 month share price return and 37.10% 3 month share price return building on a 205.56% 1 year total shareholder return. This suggests momentum is still firmly on Tango Therapeutics' side. If this kind...
  Dec 14, 2025 - $TNGX
• Can Tango Therapeutics (TNGX) Climb 37.28% to Reach the Level Wall Street Analysts Expect?
  The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 37.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Dec 8, 2025 - $TNGX
• Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
  BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 1:30pm ET. The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webca
  Nov 26, 2025 - $TNGX
• Novavax, UniFirst, and More Stocks See Action From Activist Investors
  13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
  Nov 22, 2025 - $TNGX
• Wall Street Analysts See a 46.07% Upside in Tango Therapeutics (TNGX): Can the Stock Really Move This High?
  The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 46.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Nov 21, 2025 - $TNGX
• How Investors May Respond To Tango Therapeutics (TNGX) Posting First Profit on Surging Q3 Revenue
  Tango Therapeutics, Inc. reported third quarter 2025 results showing revenue rising to US$53.81 million and a shift from a net loss to a net income of US$15.88 million versus the prior year. This marks the company's first profitable quarter in at least a year and reflects a very large year-on-year revenue increase. We'll examine how this sharp turnaround in profitability shapes Tango Therapeutics' investment narrative moving forward. Trump has pledged to "unleash" American oil and gas and...
  Nov 14, 2025 - $TNGX
• Tango Therapeutics (TNGX): Evaluating Valuation Following Strong Revenue Growth and Doubling Share Price
  Tango Therapeutics (TNGX) has posted healthy annual revenue growth of 23%, along with a near doubling in share price over the past year. Investors are keeping an eye on these trends to gauge what is next for the company. See our latest analysis for Tango Therapeutics. Tango Therapeutics’ shares have more than doubled in price year-to-date, signaling a surge of optimism after several clinical updates and partnership news in the biotech space. While the 1-year total shareholder return sits just...
  Nov 14, 2025 - $TNGX